Handel nachbörslich: .06

Nkgen Biotech Inc (NKGN)

Überblick Nachrichten Preisverlauf Warum fällt NKGN? Forum Prognose

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

NKGen Biotech Expands Convertible Financing Through New Agreement - The Globe and Mail

NKGen Biotech (NKGN) takes $2.42M note, lifts consideration shares - Stock Titan

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga

NKGen Biotech Expands Financing Through New Convertible Loan - TipRanks

NKGen Biotech (NKGN) expands AlpineBrook convertible deal with $412.5K note and new warrant - Stock Titan

Nkgen Biotech expands clinical trial site network for Alzheimer’s disease program across US - marketscreener.com

Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US - TradingView

NKGen Biotech Inc. is expanding its Alzheimer’s disease clinical trial site network nationwide across the United States. - Bitget

NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment - marketscreener.com

New Alzheimer’s trial sites move NK cell therapy closer to East Coast patients - Stock Titan

Number of shareholders of NKGen Biotech Inc. – OTC:NKGN - TradingView

NKGen Biotech Secures Additional Convertible Financing and Warrants - TipRanks

NKGen Biotech (NKGN) expands dilutive note deal with 12M+ shares, warrant - Stock Titan

NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

NKGen Biotech Announces Major Convertible Financing and Governance Shift - TipRanks

NKGen Biotech (NKGN) inks $39,922,134.22 secured convertible loan and control rights - Stock Titan

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - marketscreener.com

NKGen Biotech to Present Troculeucel Mechanism Data in - GlobeNewswire

Former Bio Firm Executive Charged for Insider Trading on Drug Approval Tip - Seoul Economic Daily

NKGen reports cognitive stability in moderate Alzheimer’s trial By Investing.com - Investing.com Australia

NKGen reports cognitive stability in moderate Alzheimer’s trial - Investing.com

As of January 31, 2026, the latest financial data disclosed by Western Asset Municipal High Income Fund Inc shows that its total net asset value has reached 154.63 millions USD. - Bitget

NKGen Biotech Inc. (hereinafter referred to as NKGen Biotech) announced the integrated Phase 1 clinical trial data for its candidate therapy Troculeucel at the Ad/Pd 2026™ conference. - Bitget

NKGen Biotech Reports Combined Phase 1 Troculeucel Data - GlobeNewswire

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ - Yahoo Finance

Troculeucel Linked to Plasma GFAP Changes and Cognitive Measures in Early Alzheimer Disease Studies - NeurologyLive

NKGen Biotech Korea Co., Ltd.: Dividend historical data and projections - marketscreener.com

Troculeucel may boost cognition, new Alzheimer’s data shows - Longevity.Technology

NKGen to present Alzheimer’s therapy data at AD/PD conference - Investing.com India

NKGen to present Alzheimer’s therapy data at AD/PD conference By Investing.com - Investing.com Canada

NKGen Biotech to Present Integrated Phase 1 Clinical and - GlobeNewswire

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026 - Yahoo Finance

Net income of NKGen Biotech Inc. – OTC:NKGNW - TradingView

NKGen Biotech Secures Additional Debt Financing from AlpineBrook - TipRanks

Nkgen Biotech amends loan agreement to secure additional $343,000 funding - Investing.com

NKGen Biotech Adds $343,000 via Fourth Amendment to AlpineBrook Secured Note; Principal Now $27.1M - TradingView

NKGen Biotech (NKGN) adds $343,000 under AlpineBrook note - Stock Titan

NKGen Biotech, Inc. and NKGen Operating Biotech, Inc. Enter Amendment to Secured Promissory Note Increases Loan Principal and Funding - marketscreener.com

NKGNNKGen Biotech Inc Latest Stock News & Market Updates - Stock Titan

NKGen Biotech increases loan principal by $251,000 under amended agreement By Investing.com - Investing.com Nigeria

NKGen Biotech increases loan principal by $251,000 under amended agreement - Investing.com South Africa

NKGen Biotech expands debt financing with loan amendment - TipRanks

NKGen Biotech Signs Amendment to Secured Promissory Note With AlpineBrook Capital - TradingView

Pre-Market Top Gainer: NKGNW NKGen Warrants NASDAQ $0.0301 Feb 2026: key setup - Meyka

Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ) - Defense World

NKGen Biotech amends loan agreement and extends forward purchase deal By Investing.com - Investing.com Nigeria

NKGen Biotech amends loan agreement and extends forward purchase deal - Investing.com

NKGen Biotech Signs Multiple Financing Agreements - TradingView

NKGen Biotech Secures Additional Funding via Note Amendment - TipRanks

Ähnlich wie NKGN